A phase IIa pharmacokinetic and efficacy study of amonafide (AS1413) in combination with cytarabine in patients with acute myeloid leukemia

被引：0
|
作者：
Lundberg, A. S.
Allen, S. L.
机构：
[1] Antisoma, Cambridge, MA USA
[2] North Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps278
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS278
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML
    Allen, Steven L.
    Erba, Harry P.
    Rizzieri, David A.
    O'Donnell, Margaret
    Powell, Bayard
    Lundberg, Ante S.
    Bennett, John M.
    Capizzi, Robert L.
    BLOOD, 2008, 112 (11) : 1019 - 1020
  • [2] Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.
    Erba, Harry P.
    O'Donnell, Margaret
    Allen, Steven L.
    Baer, Maria R.
    Powell, Bayard L.
    Stone, Richard M.
    Bennett, John M.
    Lundberg, Ante S.
    Capizzi, Robert L.
    Rizzieri, David A.
    BLOOD, 2009, 114 (22) : 433 - 434
  • [3] A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE)
    Stone, R. M.
    Allen, S. L.
    Pigneux, A.
    Stuart, R. K.
    Wetzler, M.
    Rizzieri, D.
    Erba, H. P.
    Damon, L. E.
    Jang, J. H.
    Tallman, M. S.
    Warzocha, K.
    Masszi, T.
    Sekeres, M. A.
    Miklos, E.
    Horst, H.
    Selleslag, D. L. D.
    Solomon, S. R.
    Venugopal, P.
    Lundberg, A. S.
    Powell, B. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia
    Allen, Steven L.
    Kolitz, Jonathan E.
    Lundberg, Ante S.
    Bennett, John M.
    Capizzi, Robert L.
    Budman, Daniel R.
    LEUKEMIA RESEARCH, 2010, 34 (04) : 487 - 491
  • [5] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
    Attar, Eyal C.
    De Angelo, Daniel J.
    Supko, Jeffrey G.
    D'Amato, Ferdinando
    Zahrieh, David
    Sirulnik, Andres
    Wadleigh, Martha
    Ballen, Karen K.
    McAfee, Steve
    Miller, Kenneth B.
    Levine, James
    Galinsky, Ilene
    Trehu, Elizabeth G.
    Schenkein, David
    Neuberg, Donna
    Stone, Richard M.
    Amrein, Philip C.
    CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1446 - 1454
  • [6] Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia
    Stone, Richard M.
    Mazzola, Emanuele
    Neuberg, Donna
    Allen, Steven L.
    Pigneux, Arnaud
    Stuart, Robert K.
    Wetzler, Meir
    Rizzieri, David
    Erba, Harry P.
    Damon, Lloyd
    Jang, Jun-Ho
    Tallman, Martin S.
    Warzocha, Krzysztof
    Masszi, Tamas
    Sekeres, Mikkael A.
    Egyed, Miklos
    Horst, Heinz-August
    Selleslag, Dominik
    Solomon, Scott R.
    Venugopal, Parameswaran
    Lundberg, Ante S.
    Powell, Bayard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) : 1252 - +
  • [7] A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
    Aslostovar, Lili
    Boyd, Allison L.
    Almakadi, Mohammed
    Collins, Tony J.
    Leong, Darryl P.
    Tirona, Rommel G.
    Kim, Richard B.
    Julian, Jim A.
    Xenocostas, Anargyros
    Leber, Brian
    Levine, Mark N.
    Foley, Ronan
    Bhatia, Mickie
    BLOOD ADVANCES, 2018, 2 (15) : 1935 - 1945
  • [8] FINAL RESULTS OF A PHASE 2 PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) STUDY OF COMBINATION VORELOXIN AND CYTARABINE IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
    Roboz, J.
    Lancet, J.
    Cripe, L.
    Ravandi, F.
    List, A.
    Fox, J.
    Michelson, G.
    Karp, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 31 - 31
  • [9] Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
    Ravandi, Farhad
    Cortes, Jorge E.
    Jones, Daniel
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Konopleva, Marina Y.
    O'Brien, Susan
    Estrov, Zeev
    Borthakur, Gautam
    Thomas, Deborah
    Pierce, Sherry R.
    Brandt, Mark
    Byrd, Anna
    Bekele, B. Nebiyou
    Pratz, Keith
    Luthra, Rajyalakshmi
    Levis, Mark
    Andreeff, Michael
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1856 - 1862
  • [10] Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Cripe, Larry D.
    Maris, Michael
    List, Alan F.
    Fox, Judith
    Michelson, Glenn C.
    Karp, Judith
    BLOOD, 2009, 114 (22) : 263 - 264
12345